Moderna says possible allergic reactions to COVID-19 vaccine under investigation

(Reuters) – Moderna Inc said on Tuesday it received a report from the California Department of Health that several people in a San Diego center had been treated for possible allergic reactions to its COVID-19 vaccine from a particular batch .

The company’s comments come after California’s leading epidemiologist issued a statement on Sunday recommending that suppliers halt vaccination of batch no. 41L20A due to possible allergic reactions under investigation.

“A higher than usual number of possible allergic reactions have been reported with a specific lot of Moderna vaccine given at a community vaccination clinic. Fewer than 10 people required medical attention in a 24 hour period,” said the epidemiologist in a press release. .

The vaccine manufacturer said it was not aware of any comparable cases of adverse events from other vaccination centers that may have administered vaccines from the same lot or from other lots of its vaccine.

A total of 307,300 doses from the batch remain in stock, Moderna said, out of the 1,272,200 total doses produced in the batch.

Moderna said she was working closely with U.S. health regulators to understand the cases and whether stopping use of the lot was warranted.

Nearly one million doses of the batch have already been distributed to approximately 1,700 vaccination sites in 37 states, Moderna said. (bit.ly/39MPtlF)